New Treatment Approach in Indian Visceral Leishmaniasis: Single-Dose Liposomal Amphotericin B Followed by Short-Course Oral Miltefosine

• Published in: Clinical infectious diseases Vol. 47; no. 8; pp. 1000 - 1006
• Main Authors: Sundar, Shyam, Rai, M., Chakravarty, J., Agarwal, D., Agrawal, N., Vaillant, Michel, Olliaro, Piero, Murray, Henry W.
• Format: Journal Article
• Language: English
• Published: Chicago, IL The University of Chicago Press 15.10.2008; University of Chicago Press; Oxford University Press
• Subjects: Adult; Amphotericin B - administration & dosage; Amphotericin B - adverse effects; Amphotericin B - therapeutic use; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antifungal agents; Antiparasitic agents; Articles and Commentaries; Biological and medical sciences; Dosage; Drug resistance; Drug therapy; Drug Therapy, Combination; Experimentation; Female; Human protozoal diseases; Humans; India; Infectious diseases; Intravenous injections; Leishmaniasis, Visceral - drug therapy; Leshmaniasis; Male; Medical cures; Medical research; Medical sciences; Parasites; Parasitic diseases; Pharmacology. Drug treatments; Phosphorylcholine - administration & dosage; Phosphorylcholine - adverse effects; Phosphorylcholine - analogs & derivatives; Phosphorylcholine - therapeutic use; Protozoal diseases; Skin diseases; Sodium; Treatment Outcome; Tropical medicine; Visceral leishmaniasis; Asia; India; Bihar India; Antineoplastic agent; Protozoal disease; Single dose; Oral administration; Phospholipid; Kala azar; Leishmaniasis; Parasitosis; Infection; Antiprotozoal agent; Miltefosine; Antibiotic; Antifungal agent; Treatment; Amphotericin B; Polyenic compound; Lysophospholipid; Parasiticide; Indian

Background. In Bihar, India, home to nearly one-half of the world's burden of visceral leishmaniasis, drug resistance has ended the usefulness of pentavalent antimony, which is the traditional first-line treatment. Although monotherapy with other agents is available, the use of 2 drugs with dif...